… However, based on current knowledge, we recommend that ICIs should be offered to kidney
… that targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in …

… indiscriminately target CTLA-4 and PD-1/PD-L1 pathways in … effects of PD-L1 blockade
to be uncoupled from irAE. As a … two clinical trials of advanced renal cell carcinoma (104,106), …

… anti-cancer effects as well as toxicity issues. One example is … has been found to enhance
the effectiveness of anti-PD1 and … by mTORC2 loss and uncoupled from longevity. Science (…

… Autoantibody-mediated toxicities include renal,23 … an mTOR inhibitor to PD-1 blockade has
been found to promote maintenance of allograft tolerance and continued antitumor efficacy in …

… immunosuppressive regimen before and during PD-1 blockade did not seem to mitigate the
… Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal …

… the PD-1 inhibitor cemiplimab in kidney transplant recipients (… was safety and toxicity,
specifically the rate of kidney allograft … from trials investigating their efficacy. To our knowledge, we …

… Renal toxicities have been increasingly recognized as … CTLA-4 and PD-1/PD-L1 receptor
blockade regulates immune … the safety and efficacy of these agents in kidney transplant …

… Another study reported the case of a patient who had undergone HLA-identical kidney … ,
suggesting that mTOR inhibitors may uncouple the toxicity and efficacy of anti–PD-1 agents in …

… elevated mTORC1 signaling in lesions of TSC patients such as renal … blockade, such as
anti-PD-1 or anti-PD-L1, with mTOR … toxicity profiles over mTOR/PI3K kinase domain inhibitors. …

… kidney transplants receiving anti PD-1, describes that a switch from a calcineurin inhibitor to
a mammalian target of rapamycin (mTOR… Further studies exploring the efficacy and toxicity in …